Patient Diagnostic Workup Practices

Opinion
Video

Naveen Pemmaraju, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss diagnostic practices and prognostic factors for patients with myelofibrosis.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Related Content
Data from the REVEAL trial support identifying history of thromboembolic events as a potential novel risk factor in those with polycythemia vera.

Observational Data Highlight Factors for Polycythemia Vera Progression

Megan Hollasch
June 14th 2024
Article

Data from the REVEAL trial support identifying history of thromboembolic events as a potential novel risk factor in those with polycythemia vera.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Matthew Fowler
July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

High-grade cytokine release syndrome in the WU-CART-007 1001 trial was manageable with supportive care.

WU-CART-007 Shows Preliminary Activity in Leukemia, Lymphoma Subtypes

Ashling Wahner
June 14th 2024
Article

High-grade cytokine release syndrome in the WU-CART-007 1001 trial was manageable with supportive care.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Patients with 1 prior line of therapy had improved outcomes on acalabrutinib compared with those who had 2 or more prior lines.

Acalabrutinib Shows Survival Improvement in CLL When Used Earlier

Dylann Cohn-Emery
June 14th 2024
Article

Patients with 1 prior line of therapy had improved outcomes on acalabrutinib compared with those who had 2 or more prior lines.

TRANSCEND NHL 001 subgroup analysis found that liso-cel may be more effective for patients with mantle cell lymphoma in earlier lines of treatment.

MCL Subgroup Analysis Finds Liso-cel May Be More Effective in Earlier LOT

Ariana Pelosci
June 14th 2024
Article

TRANSCEND NHL 001 subgroup analysis found that liso-cel may be more effective for patients with mantle cell lymphoma in earlier lines of treatment.